The clinical trial, sponsored by Charles University, evaluates the safety and efficacy of incretin-based therapies (GLP-1 agonists and DPP-4 inhibitors) in patients with Type 2 diabetes mellitus. Given the increasing prevalence of diabetes and associated cardiovascular complications, this study could provide critical insights into the long-term safety profiles of these therapies, potentially influencing prescribing practices and market dynamics. The results may enhance the competitive positioning of existing therapies like Exenatide and Linagliptin against newer entrants in the diabetes treatment landscape. Furthermore, the findings could support claims for expanded indications or improved patient management strategies, thereby impacting market access and reimbursement considerations.